In addition, adequate storage, processing and shipment of samples from remote areas, with equatorial climates, to the reference laboratory can also have a negative impact on PCR results

In addition, adequate storage, processing and shipment of samples from remote areas, with equatorial climates, to the reference laboratory can also have a negative impact on PCR results. classified as Mpox+; 124 (26.8%) had antibodies to at least one of the three Mpox peptides. The proportion of antibody positive samples was significantly higher in Mpox positive samples (36.9%) versus negative (21.6%) (p< 0.001). By combining PCR and serology, 66 additional patients were identified, leading to an Mpox contamination rate of 48.2% (223/463) versus 33.9% when only PCR positivity is considered. Mpox infections were as such identified in 14 additional health Bexarotene (LGD1069) zones and 23 additional outbreaks (111/174 (63.8%)versus 88/174 (50.6%)). Our findings highlight the urgent need of rapid on-site diagnostics to circumvent Mpox spread. Keywords:Mpox, multiplex serology, outbreak, Democratic Republic of the Congo == 1. Introduction == Mpox, previously called Monkeypox (MPX), is usually a zoonosis caused by the Monkeypox computer virus (MPXV) from theOrthopoxgenus. Mpox occurs mainly in central and west Africa and causes a disease with symptoms similar to those previously observed in smallpox patients [1,2,3]. The Bexarotene (LGD1069) first case of Mpox in humans was identified in 1970 in the Democratic Republic of the Congo (DRC) [4]. With the eradication of smallpox in 1980, human Mpox cases have increasingly been reported in central and west Africa. Before 2022, 11 African countries have reported human cases of Mpox, i.e., Benin, Cameroon, the Central African Republic (CAR), Cote dIvoire, DRC, Gabon, Liberia, Nigeria, the Republic of the Congo (RC), Sierra Leone and South Sudan [5,6,7]. The highest burden of the disease is usually reported in DRC, where more than 90% of Mpox cases occurred. Nevertheless, sporadic cases have been documented outside Africa, but usually with an epidemiologic link to the continent [8,9]. There are also two distinct clades of MPXV viruses; clade I circulates in Central Africa (Congo Basin) and clade II in West Africa, with the latter clade being less pathogenic [1,5,9,10]. Mpox has been considered as a rare and neglected disease, but the recent large outbreak that started in May 2022 and infected more than 80,000 individuals in more than 100 countries over the world highlighted the global public health threat of Mpox [11,12]. Mpox outbreaks are supposed to be the result of spillover events from animals to humans, and subsequent human-to-human transmission chains are limited to a few individuals [7,13]. But the recent global outbreak, which was caused by a strain close to one from an outbreak in 2017 in Nigeria [9,11,13], suggests that human transmission has been ongoing for a longer period than previously thought. The new strains have been classified as clade IIb or III depending on the authors [14,15]. The true burden of Mpox in Africa is not known and it cannot IL1A be excluded that human transmission and pauci-or asymptomatic infections are underestimated in Africa. In DRC, the highest affected country in Africa, Mpox is usually one of 21 reportable diseases or health events in the national Integrated Disease Surveillance and Response (IDSR) program. The majority of Mpox cases occur in remote areas and case reporting is thus mainly based on clinical signs according to the WHO case definition [14,16]. Mpox disease can resemble various other diseases with generalized skin eruption or rash-like measles, bacterial skin infections, scabies and chickenpox, also known as varicella [17]. The high similarities in the clinical presentation of varicella can lead to up to 50% of varicella cases that are confused with Mpox [2,18,19,20,21]. Moreover, Mpox/varicella coinfections can also occur [22]. Based on clinical signs only, there is thus likely an overestimation of Mpox cases. Since 2004, confirmatory testing by polymerase chain reaction (PCR) in DRC, is only available in the National Reference Laboratory at the Institut National de Recherche Biomdicale (INRB) located in Kinshasa, the capital city, but is usually rarely performed to confirm clinically notified case numbers. The most suitable specimens for laboratory confirmation are swabs or crusts from the skin lesions. Blood is not recommended for molecular diagnosis because of the short and variable viremic period [2,14]. However, remote health care centers are often not equipped to safely collect Bexarotene (LGD1069) crusts or swab samples, and instead blood samples are collected and shipped to the reference laboratory for the large majority of cases. Underestimation of clinically confirmed cases by PCR in the reference laboratory is thus very likely, especially for patients in remote areas who often appear with a delay after the onset of symptoms. In addition, adequate storage, processing and shipment of samples from remote areas, with equatorial climates, to the reference laboratory can also have a negative impact on PCR results. Therefore, antibody detection could be an alternative and complementary test to confirm Mpox infections. IgG antibodies can be detected soon after a rash [2]. However, the challenges with serological assays are cross-reactions with other orthopox viruses because they share many conserved.